Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

As Nexavar’s Oncology Potential Grows, So Do Bayer’s Sales Predictions

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm says the kidney cancer drug’s additional indications in liver cancer and potentially other cancers will raise peak sales beyond €500 million.

You may also be interested in...



Onyx Accuses Bayer of a Double-Cross Over a Compound Related to Nexavar

Bayer pursued a “surreptitious” plan to supplant the cancer drug at the heart of a 15-year-old collaboration, according to a harshly-worded lawsuit.

Onyx Accuses Bayer of a Double-Cross Over a Compound Related to Nexavar

Bayer pursued a “surreptitious” plan to supplant the cancer drug at the heart of a 15-year-old collaboration, according to a harshly-worded lawsuit.

Bayer/Onyx’s Nexavar Gets Liver Cancer Indication

Sorafenib becomes first systemic drug therapy approved for unresectable HCC.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month

Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings

Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits

FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals

See All
UsernamePublicRestriction

Register

PS065453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By